BMRN Biomarin Pharmaceutical

94.855

-0.215-0.23%

Trading Session 08/12 14:46 ET

High

95.430

Open

94.750

Turnover

51.91M

Low

94.140

Pre Close

95.070

Volume

547.47K

Intraday

Price Forecast

No Data

Comment

Announcement

Roche (RHHBY) Influenza Drug Gets FDA Nod for Children
Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.
08-12 10:06 ET
MQS Management LLC Takes $390,000 Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
MQS Management LLC purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) during the first quarter, according to its most recent 13F filing with the Securities & Exchan
08-12 09:11 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), BioMarin Pharmaceutical (BMRN) and Enovis (ENOV)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arbutus Biopharma (ABUS – Research Report), BioMarin Pharmaceutical (BMRN – Research Report) and Enovis (ENOV – Resear
08-12 05:25 ET
Credit Suisse Group Increases BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $111.00
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) had its price target lifted by equities researchers at Credit Suisse Group to $111.00 in a research report issued on Tuesday, Stock Target Advisor
08-11 03:51 ET
BioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $128.00 at Piper Sandler
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) had its target price boosted by equities research analysts at Piper Sandler from $125.00 to $128.00 in a research note issued to investors on Tuesd
08-11 03:11 ET
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Upgraded by StockNews.com
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) was upgraded by equities research analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued to clients and invest
08-11 02:41 ET
Great Lakes Advisors LLC Trims Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Great Lakes Advisors LLC cut its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 38.1% during the first quarter, according to its most recent 13F filing with the Securities an
08-10 10:31 ET
CIBC Asset Management Inc Reduces Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
CIBC Asset Management Inc lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 71.0% during the 1st quarter, according to its most recent disclosure with the Sec
08-10 08:31 ET
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bu
08-09 11:16 ET
BioMarin Pharmaceutical Price Target Raised to $128.00/Share From $125.00 by Piper Sandler
08-09 07:31 ET · Latest

Company Overview More

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

CEO： Bienaime M.B.A., MBA, Jean-Jacques

Market： NASDAQ

Hot List

TradeSearchNews

SymbolLatest price%Chg